Conformational Plasticity of Orthosteric Pocket Enables the Discovery of a Novel PAD4-Selective Inhibitor
ACS Chemical Biology · 2026-11-18
DOI: 10.1021/acschembio.6c00655 ↗At a glance
Journal article in ACS Chemical Biology, published online on 2026-11-18. Written by Masaya Yamaguchi and 22 co-authors. Institution: Medicine Design, Pfizer Inc., Groton, Connecticut06340, United States. 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Pfizer.
Abstract (original language)
Peptidyl-arginine deiminase (PAD) family enzymes are pivotal enzymes that catalyze the citrullination of arginine in substrate proteins. Elevated levels of citrullinated proteins are tightly linked to the incidence of rheumatoid arthritis, neurodegenerative diseases, and cancers, thus highlighting PAD enzymes as important therapeutic targets. Although several PAD isozyme-selective and non-selective small molecule inhibitors have been reported over the last decade, it remains important to identify distinct ligands that may offer differentiated therapeutic potential or selectivity. Herein, we present a PAD4-selective inhibitor identified through a structure-based virtual screen, which binds to a distinct site from known inhibitors. Biochemical and biophysical characterizations show that the inhibitor is selective for PAD4 over PAD1/PAD2/PAD3 via targeting the orthosteric site preferably at low calcium concentrations. A co-crystal structure of the inhibitor-bound PAD4 shows that the inhibitor binds to an unprecedented pocket near the catalytic site present at low calcium concentrations and stabilizes the catalytically inactive conformation. Owing to its distinctive binding site, this inhibitor series is designated as “Orthosteric B inhibitors”. Structural analysis suggests a unique conformational plasticity of the PAD4 catalytic module, which may help rationalize the PAD4 selectivity of Orthosteric B inhibitors. Further structure-based drug design and computational approaches enabled optimization of the hit to afford a potent PAD4 inhibitor capable of blocking PAD4-mediated protein citrullination in human neutrophils.
Subjects
Author keywords
Authors and institutions
- Medicine Design, Pfizer Inc., Groton, Connecticut06340, United States.
- Inflammation and Immunology Research, Pfizer Inc., Cambridge, Massachusetts02139, United States.
- Medicine Design, Pfizer Inc., Cambridge, Massachusetts02139, United States.
ORCID profiles: Masaya Yamaguchi, Chulho Choi, Gary M Chinigo, Jennifer Davoren, Stephen W Wright, Fabien Vincent, Huixian Wu, Mark E Schnute
Funding
- Pfizer
Cite
APA
Yamaguchi, M., Choi, W. Y., Chang, J. S., Sahasrabudhe, P. V., Choi, C., Chinigo, G. M., Balbo, P., McClendon, C. L., Perry, I., Xing, L., Dakin, L. A., Davoren, J., Trujillo, J. I., Wright, S. W., Parikh, M. D., Lovering, F., Futatsugi, K., Torella, R., Banker, M. E., …, & Schnute, M. E. (2026). Conformational Plasticity of Orthosteric Pocket Enables the Discovery of a Novel PAD4-Selective Inhibitor. ACS Chemical Biology. https://doi.org/10.1021/acschembio.6c00655
Vancouver
Yamaguchi M, Choi WY, Chang JS, Sahasrabudhe PV, Choi C, Chinigo GM, et al. Conformational Plasticity of Orthosteric Pocket Enables the Discovery of a Novel PAD4-Selective Inhibitor. ACS Chemical Biology. 2026. doi:10.1021/acschembio.6c00655
BibTeX
@article{Yamaguchi2026,
author = {Yamaguchi, Masaya and Choi, Won Young and Chang, Jeanne S and Sahasrabudhe, Parag V and Choi, Chulho and Chinigo, Gary M and Balbo, Paul and McClendon, Christopher Lee and Perry, Ian and Xing, Li and Dakin, Leslie A and Davoren, Jennifer and Trujillo, John I and Wright, Stephen W and Parikh, Mihir Dineshkumar and Lovering, Frank and Futatsugi, Kentaro and Torella, Rubben and Banker, Mary Ellen and Vincent, Fabien and Horst, Reto and Wu, Huixian and Schnute, Mark E},
title = {Conformational Plasticity of Orthosteric Pocket Enables the Discovery of a Novel PAD4-Selective Inhibitor},
journal = {ACS Chemical Biology},
year = {2026},
doi = {10.1021/acschembio.6c00655}
}
EUVIMED